Table 1. Clinical features, HBV genotype, and additional N-glycosylation mutation in the 778 patients enrolled in the study.
| Item | HCC (n = 193) | CHB (n = 433) | ACLF (n = 152) | P Value |
|---|---|---|---|---|
| Age (year) | 53.51 ± 10.94 | 39.80 ± 13.91 | 46.11 ± 11.5 | < 0.001 |
| Sex (M/F) | 168/25 | 365/68 | 125/27 | 0. 532 |
| HBV genotype B/genotype C | 14/179 | 62/365 | 30/120 | 0.002 |
| Anti-HBs (+/-) | 76/117 | 205/228 | 7/145 | < 0.001 |
| HBeAg (+/-) | 100/93 | 295/135 | 62/90 | < 0.001 |
| HBeAb (+/-) | 109/84 | 188/242 | 65/87 | 0.007 |
| ALT (U/L) | 73.3 (27.5-81.5) | 223.7 (40-262) | 265.2 (57-349) | < 0.001 |
| TBIL (mmol/L) | 36.6 (15.2-21.25) | 56.3 (11.5-52.2) | 321.5 (206-306) | < 0.001 |
| HBV DNA (log10IU/ml) | 5.06 ± 1.82 | 5.51 ± 1.90 | 5.53 ± 1.60 | 0.013 |
| N-glycosylation mutations [n (%)] | 24 (12.37%) | 19 (4.39%) | 4 (2.63%) | < 0.001 |
HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; TBIL, total bilirubin. Chi-squared analysis of variance (ANOVA), and nonparametric Wilcoxon signed-ranked test were used. P values less than 0.05 were considered to be statistically significant.